OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Show Description +

Dr. Danzig shares the BCVA and central subfield thickness improvements over 12 weeks for patients with diabetic macular edema treated with OCS-01 (Oculis) eye drops in the DIAMOND-Stage 1 trial.

Posted: 5/16/2025

Keywords:

retina-meeting-recap

•

OCS-01

•

Clinical Trials

•

Oculis

•

Diabetic macular edema, DME

•

BCVA

•

central subfield thickness

•

drops

Up Next

Name: OCS-01 (Oculis) in DME: A Phase 3 Update
Uploaded: 2025-05-16T21:26:21+00:00
Description: Dr. Danzig shares the BCVA and central subfield thickness improvements over 12 weeks for patients with diabetic macular edema treated with OCS-01 (Oculis) eye drops in the DIAMOND-Stage 1 trial.

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Treating DR with Axitinib

Neal S. Shah, MD

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

Back to All Videos

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Dr. Danzig shares the BCVA and central subfield thickness improvements over 12 weeks for patients with diabetic macular edema treated with OCS-01 (Oculis) eye drops in the DIAMOND-Stage 1 trial.

Posted: 5/16/2025

Keywords:

retina-meeting-recap

•

OCS-01

•

Clinical Trials

•

Oculis

•

Diabetic macular edema, DME

•

BCVA

•

central subfield thickness

•

drops

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

OCS-01 (Oculis) in DME: A Phase 3 Update

Up Next

OCS-01 (Oculis) in DME: A Phase 3 Update

More From ARVO: 2025 Coverage